health
'Like Christmas': woman’s relief after test finds she can skip chemotherapy
Karen Bonham was part of successful trial for genomic test that determines which women with breast cancer can safely avoid chemotherapy
TL;DR
- A genomic test can determine if women with breast cancer can safely avoid chemotherapy.
- An international trial showed non-inferiority in cancer-free survival rates for women who skipped chemotherapy.
- The Prosigna genomic test analyzes 50 genes in tumor tissue to assess recurrence risk.
- Patient Karen Bonham experienced immense relief after her test results indicated she could skip chemotherapy.
- While not for all patients, the test offers a path for many to avoid chemotherapy.
- The trial results will be presented at the American Society of Clinical Oncology's annual meeting.